Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2003 2
2004 1
2005 3
2006 1
2007 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.
Lancet JE, Gojo I, Gotlib J, Feldman EJ, Greer J, Liesveld JL, Bruzek LM, Morris L, Park Y, Adjei AA, Kaufmann SH, Garrett-Mayer E, Greenberg PL, Wright JJ, Karp JE. Lancet JE, et al. Among authors: bruzek lm. Blood. 2007 Feb 15;109(4):1387-94. doi: 10.1182/blood-2006-04-014357. Epub 2006 Nov 2. Blood. 2007. PMID: 17082323 Free PMC article. Clinical Trial.
A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer.
Dy GK, Bruzek LM, Croghan GA, Mandrekar S, Erlichman C, Peethambaram P, Pitot HC, Hanson LJ, Reid JM, Furth A, Cheng S, Martell RE, Kaufmann SH, Adjei AA. Dy GK, et al. Among authors: bruzek lm. Clin Cancer Res. 2005 Mar 1;11(5):1877-83. doi: 10.1158/1078-0432.CCR-04-1769. Clin Cancer Res. 2005. PMID: 15756013 Clinical Trial.
Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.
Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T, Overton RM, Ahmann G, Bruzek LM, Adjei AA, Kaufmann SH, Wright JJ, Sullivan D, Djulbegovic B, Cantor AB, Greipp PR, Dalton WS, Sebti SM. Alsina M, et al. Among authors: bruzek lm. Blood. 2004 May 1;103(9):3271-7. doi: 10.1182/blood-2003-08-2764. Epub 2004 Jan 15. Blood. 2004. PMID: 14726402 Free article. Clinical Trial.